Foresee Pharmaceuticals Foresee Pharmaceuticals Announces Dosing of First Patient in Phase 2/3 Clinical Trial of FP-025 for Treatment of COVID-19 Associated ARDS Posted on 2021-03-282021-06-03 by maxproadmin More >>
Foresee Pharmaceuticals Foresee Pharmaceuticals Enters Exclusive License Agreement with Intas Pharmaceuticals for Commercialization in the United States Posted on 2021-03-042021-03-22 by maxproadmin More >>
Foresee Pharmaceuticals Foresee Pharmaceuticals Announces Completion of US$47 Million Financing Posted on 2020-12-242021-02-07 by maxproadmin More >>
Foresee Pharmaceuticals Foresee Pharmaceuticals Enters Exclusive License Agreement with GenSci for the Commercialization of Camcevi in China Posted on 2020-11-172021-02-07 by maxproadmin More >>
Foresee Pharmaceuticals Foresee Pharmaceuticals Announces NDA for CAMCEVI™ 42MG Accepted for Review by the FDA Posted on 2020-10-092021-02-07 by maxproadmin More >>
Foresee Pharmaceuticals Foresee Pharmaceuticals to Present at the 2020 Fanconi Anemia Scientific Symposium Posted on 2020-09-172021-02-07 by maxproadmin More >>
